New and Emerging Targeted Therapies for Advanced Breast Cancer
In the United States, breast cancer is among the most frequently diagnosed cancers in women. Breast cancer is classified into four major subtypes: human epidermal growth factor receptor 2 (HER2), Luminal-A, Luminal-B, and Basal-like or triple-negative, based on histopathological criteria including t...
Main Authors: | Kristie H. Lau, Alexandra M. Tan, Yihui Shi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-02-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/4/2288 |
Similar Items
-
Advances in targeted therapy for HER2-low breast cancer
by: GUO Qing, ZHANG Jian
Published: (2023-02-01) -
New Advances in Targeted Therapy of HER2-Negative Breast Cancer
by: Junsha An, et al.
Published: (2022-03-01) -
A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
by: Jing Ma, et al.
Published: (2022-07-01) -
HER2-positive breast cancer – Available anti-HER2 therapies and new agents under investigation
by: Martyna Zielińska, et al.
Published: (2020-06-01) -
Novel HER-2 Targeted Therapies in Breast Cancer
by: Catarina Lopes Fernandes, et al.
Published: (2023-12-01)